ଡେଲାଭିର୍ଡାଇନ

ଡେଲାଭିର୍ଡାଇନ
Clinical data
Pronunciation	del a' vir deen
Trade names	Rescriptor
Synonyms	Delavirdine mesylate
AHFS/Drugs.com	monograph
MedlinePlus	a600034
Pregnancy; category	AU: B3 ; ;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Bioavailability	85%
Protein binding	98%
Metabolism	Liver (CYP3A4- and CYP2D6-mediated)
Elimination half-life	5.8 hours
Excretion	Kidney (51%) and fecal (44%)
Identifiers
	IUPAC name N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide;
Chemical and physical data
Formula	C22H28N6O3S
Molar mass	୪୫୬.୫୭ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)Nc1cccnc1N4CCN(C(=O)c3cc2cc(NS(C)(=O)=O)ccc2[nH]3)CC4;
	InChI InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3 ; Key:WHBIGIKBNXZKFE-UHFFFAOYSA-N ;
(verify)

ଡେଲାଭିର୍ଡାଇନ ( DLV ), ବେପାର ନାମ ରେସ୍କ୍ରିପ୍ଟର, ହେଉଛି ଏକ ଔଷଧ ଯାହାକି ଏଚଆଇଭି/ଏଡସ୍ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଏହା ଅନ୍ୟ ଏଚଆଇଭିଔଷଧ ସହିତ ମିଳିତ ଭାବରେ ବ୍ୟବହୃତ ହୁଏ; ଯଦିଓ ଏହା ଏକ ପସନ୍ଦଯୋଗ୍ୟ ଚିକିତ୍ସା ନୁହେଁ ।^[୨] ଏହାକୁ ଦିନକୁ ତିନିଥର ପାଟିରେ ଦିଆଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥକ୍କା, ମୁଣ୍ଡ ବୁଲାଇବା, ମୁଣ୍ଡବିନ୍ଧା ଏବଂ ରାସ ଅନ୍ତର୍ଭୁକ୍ତ ।^[୧] ଅନ୍ୟାନ୍ୟ ଲକ୍ଷଣ ମଧ୍ୟରେ ଷ୍ଟିଭେନ୍ସ-ଜନସନ ସିଣ୍ଡ୍ରୋମ, କେନ୍ଦ୍ରୀୟ ମେଦବହୁଳତା ଏବଂ ପ୍ରତିରକ୍ଷା ପୁନଃ ନିର୍ମାଣ ସିଣ୍ଡ୍ରୋମ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୨] ଏହା ଏକ ଅଣ-ନ୍ୟୁକ୍ଲିଓସାଇଡ୍ ରିଭର୍ସ ଟ୍ରାନ୍ସକ୍ରିପଟେଜ୍ ଇନହିବିଟର (NNRTI) ।^[୨]

୧୯୯୭ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଡେଲାଭର୍ଡାଇନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ୨୦୨୧ ସୁଦ୍ଧା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ବନ୍ଦ ହୋଇଯାଇଛି ।^[୨] ଏହା ସାଧାରଣ ଭାବରେ ବ୍ୟବହୃତ ହୁଏ ନାହିଁ ।^[୧]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ "Delavirdine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 23 December 2021.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ "Delavirdine Mesylate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 15 May 2016. Retrieved 23 December 2021.

[Liv2021-1] ୧.୦ ^୧.୧ ^୧.୨ "Delavirdine". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 23 December 2021.

[AHFS2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ ^୨.୭ "Delavirdine Mesylate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 15 May 2016. Retrieved 23 December 2021.

[୨]

[୧]

Clinical data


Pronunciation	del a' vir deen^[୧]
Trade names	Rescriptor
Synonyms	Delavirdine mesylate
AHFS/Drugs.com	monograph
MedlinePlus	a600034
Pregnancy category	AU: B3
Routes of administration	By mouth
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	85%
Protein binding	98%
Metabolism	Liver (CYP3A4- and CYP2D6-mediated)
Elimination half-life	5.8 hours
Excretion	Kidney (51%) and fecal (44%)
Identifiers
IUPAC name N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide
Chemical and physical data
Formula	C₂₂H₂₈N₆O₃S
Molar mass	୪୫୬.୫୭ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C)Nc1cccnc1N4CCN(C(=O)c3cc2cc(NS(C)(=O)=O)ccc2[nH]3)CC4
InChI InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3^Y Key:WHBIGIKBNXZKFE-UHFFFAOYSA-N^Y
(verify)